Fig. 4: Preserved neutralizing effect in 3N39v2 against globally spreading SARS-CoV-2 variants.
From: Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
a ACE2-Fcs and monoclonal antibody, REGN1093346 neutralized pseudotyped variants recently emerged in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) in 293T/ACE2 cells. n = 4 technical replicates. b Neutralization potency of 3N39v2-Fc and monoclonal antibody, REGN10933 against UK-B.1.1.7 and BR-P.1 was analyzed in Vero6E/TMPRSS2 cells. Data are mean ± SEM of n = 3 technical replicates.
